NYXH

NYXH

USD

Nyxoah SA Ordinary Shares

$5.870+0.010 (0.171%)

Precio en Tiempo Real

Healthcare
Medical Instruments & Supplies
Bélgica

Gráfico de Precios

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$5.860

Máximo

$6.058

Mínimo

$5.850

Volumen

0.00M

Fundamentos de la Empresa

Capitalización de Mercado

228.1M

Industria

Medical Instruments & Supplies

País

Belgium

Estadísticas de Negociación

Volumen Promedio

0.13M

Bolsa

NGM

Moneda

USD

Rango de 52 Semanas

Mínimo $5.55Actual $5.870Máximo $12.21

Noticias Relacionadas

PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to ...

Ver más
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
Analyst Upgrades

Stifel Maintains Buy on Nyxoah, Lowers Price Target to $14

Stifel analyst Jonathan Block maintains Nyxoah with a Buy and lowers the price target from $15 to $14.

Ver más
Stifel Maintains Buy on Nyxoah, Lowers Price Target to $14
GlobeNewswire

Conditional Issuance of Shares

INSIDE INFORMATIONREGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"),

Ver más
Conditional Issuance of Shares
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to ...

Ver más
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Nyxoah, Maintains $15 Price Target

HC Wainwright & Co. analyst Edward White reiterates Nyxoah with a Buy and maintains $15 price target.

Ver más
HC Wainwright & Co. Reiterates Buy on Nyxoah, Maintains $15 Price Target
GlobeNewswire

Nyxoah Provides Update on FDA Approvable Letter for Genio System

Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET –

PR Newswire

NYXH Investors Have Opportunity to Join Nyxoah S.A. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nyxoah S.A....

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.